Active, not recruitingInterventional · Phase 1NCT02732275 ↗A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With LymphomasJia RuanPIInterventionDrug: DS-3201bDatesMar 2016 – Dec 2022
RecruitingInterventional · Phase 2NCT02974647 ↗Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaJia RuanPIInterventionDrug: RuxolitinibDatesNov 2016 – Nov 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterLymphoma
RecruitingExpanded accessNCT03601442 ↗Managed Access Programs for CTL019, TisagenlecleucelGaurav VarmaPIInterventionBiological: CTL019DatesStarted Dec 2019SponsorNovartis Pharmaceuticals CorporationLymphomaLeukemiaOff-label Indications
RecruitingInterventional · Phase 1NCT04301076 ↗A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)Jia RuanPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Doxorubicin Hydrochloride · Procedure: Echocardiography Test · Drug: Etoposide · Drug: Lenalidomide · Procedure: Multigated Acquisition Scan · Procedure: Positron Emission Tomography · Drug: Prednisone · Drug: Vincristine SulfateDatesAug 2021 – Jun 2027 (est.)SponsorNational Cancer InstituteAcute Adult T-Cell Leukemia/LymphomaAdult T-Cell Leukemia/LymphomaChronic Adult T-Cell Leukemia/Lymphoma+1 more
RecruitingInterventional · Phase 1NCT05798897 ↗A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)Caitlin K GribbinPIInterventionDrug: MT-601DatesJan 2023 – Feb 2028 (est.)SponsorMarker Therapeutics, Inc.Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more
Active, not recruitingInterventional · Phase 2NCT05951959 ↗A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)Jia RuanPIInterventionDrug: Acalabrutinib · Drug: Venetoclax · Drug: RituximabDatesDec 2023 – Oct 2028 (est.)SponsorAstraZeneca, PLCMantle Cell Lymphoma (MCL)
RecruitingInterventional · Phase 1NCT07082803 ↗An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin LymphomasErin MulveyPIInterventionDrug: TLN-121 · Drug: zeprumetostat (TLN-254)DatesJun 2025 – Sep 2030 (est.)SponsorTreeline Biosciences INCLymphomaLymphoma, Non Hodgkin
CompletedInterventional · Phase 1NCT04231747 ↗A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTsiporah B ShorePIInterventionBiological: CC-97540DatesMay 2020 – Feb 2024SponsorJuno Therapeutics, Inc.Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
CompletedInterventional · Phase 1/2NCT04673617 ↗A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.Tsiporah B ShorePIInterventionDrug: AB-101 · Drug: Rituximab · Drug: Interleukin-2 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: BendamustineDatesMar 2021 – Oct 2025SponsorArtiva Biotherapeutics, Inc.Non Hodgkin Lymphoma
TerminatedInterventional · Phase 3NCT05181540 ↗A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)Tsiporah B ShorePIInterventionBiological: AB-205 · Other: PlaceboDatesFeb 2022 – Dec 2023SponsorAngiocrine Bioscience, Inc.Hodgkin LymphomaNon Hodgkin Lymphoma